Briakinumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameBriakinumab
Drug Alias NameBriakinumabum布瑞吉努单抗Anti-IL-12/23-antibody-Abbott布雷奴单抗Ozespa +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitors
TargetsInterleukin-12Interleukin-23
Therapy Area/IndicationsPlaque psoriasisPsoriasisMultiple Sclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCambridge Antibody Technology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesAbbvie IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisPsoriasisMultiple Sclerosis +[4] 

Other Information

ATC CodeL04AC09
Related LinksWikipediaDrugBankKEGG